JOEL BROOKER: Open Payments
NPI 1780953133 · ATHENS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$847 in 42 payments from 15 companies in 2025. Trend: 2023 $775 · 2024 $933 · 2025 $847
Food & beverage: $847
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 5 | $128 |
| Merck Sharp & Dohme LLC | 5 | $108 |
| Insmed, Inc. | 4 | $94 |
| GlaxoSmithKline, LLC. | 5 | $91 |
| AstraZeneca Pharmaceuticals LP | 5 | $84 |
| Grifols USA, LLC | 3 | $58 |
| Regeneron Healthcare Solutions, Inc. | 2 | $41 |
| Actelion Pharmaceuticals US, Inc. | 2 | $39 |
| HARMONY BIOSCIENCES LLC | 2 | $36 |
| Lilly USA, LLC | 2 | $35 |
Products named: DUPIXENT, WINREVAIR, Arikayce, NUCALA, Prolastin-C Liquid, TEZSPIRE, WAKIX, ZEPBOUND.
Industry payments across GA — which companies pay providers there.
